NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week released its first-quarter financial results, posting a jump in its net loss amid lower revenues and higher expenses.

The company loss for the three-month period ended March 31 rose to $26.3 million or $0.39 a share, from $9 million, or $0.15 a share, in the year-ago quarter. This year's first quarter loss does not include a $224.7 million charge related to an in-process R&D expense tied to Alnylam's January acquisition of Merck's RNAi assets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.